Royal Bank of Canada’s Nuvectis Pharma NVCT Stock Holding History

Royal Bank of Canada’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10K	Buy	1,264 +342	+37%	+$2.93K	﹤0.01%	6162
2025 Q4	$7K	Sell	922 -30,084	-97%	-$196K	﹤0.01%	6593
2025 Q3	$186K	Sell	31,006 -226	-0.7%	-$1.55K	﹤0.01%	5132
2025 Q2	$233K	Buy	+31,232	New	+$283K	﹤0.01%	5047
2024 Q2	–	Sell	-270	Closed	-$2K	–	7383
2024 Q1	$2K	Sell	270 -2,077	-88%	-$17.7K	﹤0.01%	6687
2023 Q4	$19K	Buy	2,347 +1,259	+116%	+$11.2K	﹤0.01%	6335
2023 Q3	$14K	Sell	1,088 -1,604	-60%	-$23.2K	﹤0.01%	6315
2023 Q2	$43K	Buy	+2,692	New	+$43K	﹤0.01%	5840
2022 Q4	–	Sell	-76	Closed	-$1K	–	7561
2022 Q3	$1K	Buy	+76	New	+$708	﹤0.01%	7230

Other funds holding NVCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Royal Bank of Canada's NVCT Position: Q1 2026 in Review

Royal Bank of Canada increased its Nuvectis Pharma (NVCT) stake by 37% in Q1 2026, buying an estimated $2.93K and bringing the position to 1,264 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #6162.

Royal Bank of Canada first reported a position in NVCT in Q3 2022 and has held it in 9 quarters since. The position peaked at $233K in Q2 2025. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

Royal Bank of Canada held 1,264 shares of Nuvectis Pharma worth $10K as of Q1 2026.
Royal Bank of Canada bought 342 Nuvectis Pharma shares in Q1 2026, an estimated $2.93K.
Nuvectis Pharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6162 holding.
Royal Bank of Canada first reported a position in Nuvectis Pharma in Q3 2022 and has held it in 9 quarters since.
Royal Bank of Canada's Nuvectis Pharma position peaked at $233K in Q2 2025.
62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.